Acute myelomonocytic leukemia and T-lymphoblastic lymphoma as simultaneous bilineage hematologic malignancy treated with decitabine:A case report
作者机构:Department of Internal MedicineJeonbuk National University Medical SchoolJeonju 54907South Korea Department of PathologyJeonbuk National University Medical SchoolJeonju 54907South Korea Department of Laboratory MedicineJeonbuk National University Medical SchoolJeonju 54907South Korea
出 版 物:《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期:2023年第11卷第21期
页 面:5129-5135页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题:Simultaneous bilineage hematologic malignancies Acute myelomonocytic leukemia T-lymphoblastic lymphoma Decitabine Pulmonary thromboembolism Case report
摘 要:BACKGROUND Simultaneous bilineage hematologic malignancies are rare;however,several cases of acute myeloid leukemia(AML)and T-lymphoblastic lymphoma(T-LBL)cooccurrence have been reported.A standard treatment for simultaneous AML and T-LBL has not yet been established,and its prognosis is very *** studies to develop standard treatments are required to increase patient survival *** SUMMARY A 69-year-old man complaining of pleuritic chest pain visited the emergency *** tomography revealed multiple enlarged lymph nodes(LNs)in the neck and groin and pulmonary thromboembolism with pulmonary ***,a peripheral blood smear performed due to leukocytosis revealed circulating *** myelomonocytic leukemia(AMML)was diagnosed after bone marrow examination,and T-LBL positivity for terminal deoxynucleotidyl transferase,cluster of differentiation(CD)34,and CD4 was confirmed by cervical LN *** and dexamethasone were administered because he could not receive intensive chemotherapy due to poor performance *** remission of AMML and T-LBL was achieved after 4 cycles of decitabine plus *** We report the therapeutic effect of decitabine,a hypomethylating agent(HMA),in patients with concurrent bilineage hematologic malignancies and suggest that further studies are required to evaluate the therapeutic effect of HMAs on both lymphoid and bilineage hematologic malignancies.